2 completed. 2 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 2 | Completed 2 |
Follow TH 302: new trials by email Literature Review of TH 302 trials Research Report on TH 302
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Clinical Trial Testing TH-302 in Combination With Gemcitabine in Previously Untreated Subjects With Metastatic or Locally Advanced Unresectable Pancreatic Adenocarcinoma TH-302, Gemcitabine, Placebo (5 percent dextrose - D5W) - Metastatic or Locally Advanced Unresectable Pancreatic Adenocarcinoma | Phase 3 | Completed | ImmunoGenesis | 693 | 2012-12-01 | 2025-05-11 |
| A Trial of TH-302 in Combination With Doxorubicin Versus Doxorubicin Alone to Treat Patients With Locally Advanced Unresectable or Metastatic Soft Tissue Sarcoma TH-302 in Combination with Doxorubicin, Doxorubicin - Soft Tissue Sarcoma | Phase 3 | Completed | Threshold Pharmaceuticals | 640 | 2011-09-01 | 2016-06-02 |
Neoplasm Metastasis (1) · Pancreatic Neoplasms (1) · Sarcoma (1)
ImmunoGenesis (1) · Threshold Pharmaceuticals (1)
Germany (2) · United States (2) · Austria (1) · Belgium (1) · Canada (1) · Denmark (1) · France (1) · Hungary (1) · Israel (1) · Italy (1) · Poland (1) · Russia (1) · Spain (1)
Antonio Gualberto, MD, PhD (1) · William Tap, MD (1)